Cargando…

Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD)

Detalles Bibliográficos
Autores principales:	Efebera, Yvonne A, Ruppert, Amy S, Ngankeu, Apollinaire, Garman, Sabrina, Kumchala, Prasanthi, Howard, Alan, Devine, Steven M, Ranganathan, Parvathi, Garzon, Ramiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168723/ https://www.ncbi.nlm.nih.gov/pubmed/34079960 http://dx.doi.org/10.29328/journal.ijbmr.1001007

Ejemplares similares

Modulating endothelial cells with EGFL7 to diminish aGVHD after allogeneic bone marrow transplantation in mice
por: Dorrance, Adrienne M., et al.
Publicado: (2022)

Intestinal aGVHD and infection after hematopoietic stem cell transplantation
por: Hou, Cai-yan, et al.
Publicado: (2013)

Toll-Like Receptor Stimulation by MicroRNAs in Acute Graft-vs.-Host Disease
por: Zitzer, Nina C., et al.
Publicado: (2018)

Tyrosine supplement ameliorates murine aGVHD by modulation of gut microbiome and metabolome
por: Li, Xiaoqing, et al.
Publicado: (2020)

Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies
por: Naserian, Sina, et al.
Publicado: (2020)

Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation
por: Shokouhi, Shabnam, et al.
Publicado: (2015)

The Potential Genes Mediate the Pathogenicity of Allogeneic CD4(+)T Cell in aGVHD Mouse Model
por: Yu, Zhengyu, et al.
Publicado: (2021)

Compound A Increases Cell Infiltration in Target Organs of Acute Graft-versus-Host Disease (aGVHD) in a Mouse Model
por: Bouazzaoui, Abdellatif, et al.
Publicado: (2021)

Human Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells
por: Gao, Ya, et al.
Publicado: (2021)

Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation
por: Song, Yuan, et al.
Publicado: (2020)

Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials
por: Luo, Chengxin, et al.
Publicado: (2023)

Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGVHD
por: He, Fiona, et al.
Publicado: (2016)

Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy
por: Yang, Jingjing, et al.
Publicado: (2021)

Fluvastatin-Pretreated Donor Cells Attenuated Murine aGVHD by Balancing Effector T Cell Distribution and Function under the Regulation of KLF2
por: Zhao, Kai, et al.
Publicado: (2020)

Adipose tissue-derived stem cells modulate immune function in vivo and promote long-term hematopoiesis in vitro using the aGVHD model
por: Jiang, Ming, et al.
Publicado: (2020)

Tumor necrosis factor α in aGVHD patients contributed to the impairment of recipient bone marrow MSC stemness and deficiency of their hematopoiesis-promotion capacity
por: Ding, Li, et al.
Publicado: (2020)

Berberine ameliorates aGVHD by gut microbiota remodelling, TLR4 signalling suppression and colonic barrier repairment for NLRP3 inflammasome inhibition
por: Zhao, Yanna, et al.
Publicado: (2022)

Steroid-resistant intestinal aGVHD and refractory CMV and EBV infections complicated by haplo-HSCT were successfully rescued by FMT and CTL infusion
por: Qi, Ling, et al.
Publicado: (2021)

Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier
por: Bu, Xiaoyin, et al.
Publicado: (2023)

Human Amniotic Mesenchymal Stem Cells Alleviate aGVHD after allo-HSCT by Regulating Interactions between Gut Microbiota and Intestinal Immunity
por: Bu, Xiaoyin, et al.
Publicado: (2023)

Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage
por: He, Xin, et al.
Publicado: (2016)

Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation
por: Zhu, Jinye, et al.
Publicado: (2023)

Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia
por: Ngankeu, Apollinaire, et al.
Publicado: (2017)

HMGB1 Recruits TET2/AID/TDG to Induce DNA Demethylation in STAT3 Promoter in CD4(+) T Cells from aGVHD Patients
por: Xu, Xuejun, et al.
Publicado: (2020)

Three-dimensional structure discrepancy between HLA alleles for effective prediction of aGVHD severity and optimal selection of recipient-donor pairs: a proof-of-concept study
por: Han, Hongxing, et al.
Publicado: (2015)

Enhanced alleviation of aGVHD by TGF‐β1‐modified mesenchymal stem cells in mice through shifting MΦ into M2 phenotype and promoting the differentiation of Treg cells
por: Wu, Ran, et al.
Publicado: (2019)

PB2405: BAICALIN MODULATES INTESTINAL FLORA TO TREAT AGVHD
por: Yang, Jingrong, et al.
Publicado: (2023)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
por: von Bubnoff, Nikolas, et al.
Publicado: (2018)

International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: Proposed Diagnostic Criteria for Chronic GVHD (Part I)
por: Ogawa, Yoko, et al.
Publicado: (2013)

Immunometabolic Therapeutic Targets of Graft-versus-Host Disease (GvHD)
por: Mhandire, Kudakwashe, et al.
Publicado: (2021)

Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation
por: Resende, C.B., et al.
Publicado: (2017)

Allodepleted T‐cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft‐versus‐host disease (GVHD) in the absence of GVHD prophylaxis
por: Roy, Denis Claude, et al.
Publicado: (2019)

An Intelligent Clinical Decision Support System for Predicting Acute Graft-versus-host Disease (aGvHD) following Allogeneic Hematopoietic Stem Cell Transplantation
por: Salehnasab, Cirruse, et al.
Publicado: (2021)

GVHD Prophylaxis 2020
por: Gooptu, Mahasweta, et al.
Publicado: (2021)

The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD)
por: Demosthenous, Christos, et al.
Publicado: (2021)

Editorial: Novel and Improved Methods for the Prevention and Treatment of Graft-Versus-Host Disease (GVHD)
por: Ullrich, Evelyn, et al.
Publicado: (2022)

2844. Butyrogenic Bacteria After Acute Graft vs. Host Disease Associate with the Development of Steroid Refractory GVHD
por: Golob, Jonathan L, et al.
Publicado: (2019)

Ceruloplasmin Is a Potential Biomarker for aGvHD following Allogeneic Hematopoietic Stem Cell Transplantation
por: Lv, Meng, et al.
Publicado: (2013)

P1305: HSA_CIRC_0001599 REGULATES IL18 LEVELS IN AGVHD VIA CERNA MECHANISM
por: Xia, M., et al.
Publicado: (2022)

Role of endothelial cells in graft-versus-host disease
por: Neidemire-Colley, Lotus, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pke06c5tk852423jdr3g4h3m22